- 6 years of age or older. The age limits including children and adolescents were chosen because childhood and puberty are considered to be the greatest risk for disease progression, and ARQ 092 may provide the most benefit to this young group of patients. In addition, an important objective of this study is to characterize the pharmacokinetics of ARQ 092 in the pediatric population since it has been better studied in adults.